CD274 and neoplasm: Although several, mostly tissue based, markers such as the expression of PD-L1, the tumor mutational burden (TMB) or the microsatellite instability (MSI) status have been suggested to predict ICI treatment response in selected tumor entities (3, 6–8), the identification of the ideal ICI patients who particularly benefit from ICI has remained challenging.